{"nct_id":"NCT04736706","title":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2024-11","start_date":"2021-04-14","start_date_type":"ACTUAL","primary_completion_date":"2026-10-29","primary_completion_date_type":"ESTIMATED","completion_date":"2026-10-29","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["MRK"]}